The superannuation lobby has indicated that the impact of genetic testing on insurance within superannuation will be limited due to the small proportion of policies that are underwritten. According to data from the Australian Prudential Regulation Authority (APRA), only around 10% of insurance policies within superannuation are subject to underwriting.
“Only a minority of cover through superannuation is underwritten,” stated the Association of Superannuation Funds of Australia (ASFA). “APRA data indicates that only around 10 per cent had higher cover than default levels which involved underwriting. However, this amounts to at least 900,000 individuals.”
In a submission to the Treasury supporting a ban on the use of adverse genetic testing results in life insurance, ASFA further commented, “That said, in many cases the underwritten level of cover will be below the amounts set out in the Financial Services Council moratorium document.” They added, “Only a small proportion of those with underwritten policies will have taken a relevant genetic test. A recent Australian study of individuals aged over 45 indicated that around 5 per cent had undertaken disease related genetic testing.”
Additional research from 2021 noted: “Sector research released in 2021 indicated that around 10 per cent of individuals who disclosed a genetic test result had insurance cover offered on less favourable terms or had cover declined.”
ASFA concluded: “Running through the various percentages, it is likely that currently no more than a few thousand of the 9 million or so individuals with group life cover through superannuation currently would have life cover subject to additional terms or would have cover declined because of a genetic test result. This suggests that the aggregate cost to insurers providing group cover through superannuation of banning use of adverse genetic testing will be quite low, especially given that only a proportion of individuals with an adverse genetic test result will go on to have an insurance claim.”
“However, use of genetic testing may well increase in the future, especially if there is a ban on the use of adverse genetic test results in the underwriting of insurance. The incidence of both individually underwritten insurance and higher levels of cover are greater outside of superannuation.”
